Chitosan hydrogel encapsulated with LL-37 cathelicidin peptide significantly reduced pressure ulcer area and promoted angiogenesis through HIF-1α and VEGF-A upregulation in a mouse model.
48.12%remaining wound area at day 15 with LL-37/chitosan hydrogel (significantly less than all control groups)
What the researchers found
LL-37/chitosan hydrogel significantly reduced pressure ulcer area to 48.12% by day 15, with increased epithelial thickness, capillary density, and upregulated HIF-1α and VEGF-A expression at both mRNA and protein levels.
Why it matters
Pressure ulcers affect millions of bedridden patients and are difficult to treat. A biocompatible, antibacterial, wound-healing hydrogel combining LL-37's antimicrobial and regenerative properties with sustained delivery could transform wound care.
The numbers in context
2.5% chitosan hydrogel; no cytotoxicity; enhanced TNF-alpha; faster wound healing in mice.
How the study worked
Mouse pressure ulcer model using magnets on 12/12h schedule for 21 days. Groups: LL-37/CS hydrogel (20 μg LL-37), naked LL-37 (20 μg), hydrogel alone, no treatment (n=6/group). Measured ulcer area, histology, cytotoxicity, TNF-α release, antibacterial activity, and angiogenesis markers.
Who was studied
Mice with deep tissue injuries plus NIH3T3 fibroblast cell cultures
What this study cannot tell us
Mouse model with relatively small group sizes (n=6). Mouse skin heals differently than human skin. The magnet-based pressure ulcer model may not fully replicate clinical pressure ulcer pathophysiology. Long-term healing outcomes beyond day 21 not assessed.
How to read the evidence
Preclinical animal study with well-designed controls and multiple outcome measures. Small group sizes but clear treatment effects.
When this study was published
Published in 2020. Antimicrobial peptide wound dressings continue to be developed with various delivery systems.
The bigger picture
The combination of antimicrobial peptides with biocompatible delivery systems represents a convergence of infection control and tissue regeneration. LL-37/chitosan hydrogel addresses both the infection risk and poor healing that make pressure ulcers so difficult to manage.
Questions still open
- Can LL-37/chitosan hydrogel be scaled up for clinical trials in human pressure ulcer patients?
- How does the release kinetics of LL-37 from chitosan compare to other hydrogel delivery systems?
- Would this approach work for other chronic wound types like diabetic ulcers or venous stasis wounds?
Common questions
What is LL-37?
Why use chitosan hydrogel?
Read the original research
Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model.
Military Medical Research, 7(1), 20
Citation
Yang, Xu; Guo, Jing-Lin; Han, Jing; Si, Rui-Juan; Liu, Pan-Pan; Zhang, Zi-Rui; Wang, Ai-Min; Zhang, Ju. (2020). Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model.. Military Medical Research, 7(1), 20. https://doi.org/10.1186/s40779-020-00249-5